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http:WHAT THIS PAPER ADDS
This review is the ﬁrst comprehensive analysis of angiosarcoma cases in arteriovenous ﬁstulae. Patient de-
mographics, presentation, diagnostic challenges, and management of these cases have been evaluated to a level
that has not been done previously. Therefore, this provides a useful platform for future cases and research to
use as a reference tool for this uncommon but important pathology.Objective/background: To conduct a comprehensive review of cases, presentation, diagnosis, and management
of angiosarcoma in arteriovenous ﬁstulae (AVF) created for haemodialysis.
Methods: Two authors independently conducted systematic searches and extraction of articles from the Embase,
AMED, Health Management Information Consortium, and MEDLINE databases in keeping with the inclusion/
exclusion criteria and Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards.
Results: Twenty-two unique patient cases were identiﬁed; 20 of the cases were men and mean  SD age of
presentation was 54.9  13.6 years. Nineteen cases were post-transplant and 18 were on antirejection agents.
The most common presenting symptom was pain, with or without a mass. The initial diagnosis was most often
thrombosis/infection of the AVF and the diagnostic interval to a correct diagnosis of angiosarcoma was between
2 and 40 weeks. Mean  SD time to presentation of symptoms from ﬁstula formation was 118.9  57.5 months,
while from transplant it was 96.9  70.0 months. Amputation was the most common treatment modality and
mean  SD survival was 8.8  3.7 months.
Conclusion: Angiosarcoma should be suspected in previously quiescent AVF that presents with pain. The
presence of a rapidly enlarging mass or bleeding/bruising should be taken as alarm indicators and warrant urgent
investigation in accordance with local cancer guidelines. Any surgical procedure should involve histological
samples as a matter of course.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Arteriovenous ﬁstulae (AVF) are the preferred method for
vascular access in renal failure.1 Favourable ﬂow, infection,
thrombosis, and cardiovascular outcome proﬁles compared
with both arteriovenous grafts and central venous catheters
have culminated in the “ﬁstula ﬁrst” initiative, anrresponding author.
il address: j.crane@imperial.ac.uk (J. Crane).
-5884/ 2015 European Society for Vascular Surgery. Published by
r Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2015.08.016international campaign to encourage AVF usage in patients
who require or will require renal dialysis.2
Although there are guidelines on when to form AVF,
there is little consensus on their management after trans-
plant. A recent review suggested that functioning ﬁstulae
should not be ligated post-transplant in case further dialysis
is required, unless complications such as steal syndrome,
aneurysmal disease, or ischaemia of the associated ex-
tremity exist.3 However, these complications are dependent
on blood ﬂow and therefore cannot occur in nonfunctioning
ﬁstulae. Consequently, little evidence or guidance exists
with respect to the management of the nonfunctioning
ﬁstula post-transplant. Most often with nonfunctioning
128 Y. Oskrochi et al.ﬁstulae, aesthetic and/or symptom concerns will cause
patients to seek discussion with their surgeon, resulting in a
form of surgical management, usually ligation or excision.
However, one risk that is relevant to both functioning and
nonfunctioning ﬁstulae is the occurrence of angiosarcoma
(AS). An aggressive but rare malignancy, multiple case re-
ports exist in the literature with regard to this phenome-
non; however, apart from cursory reviews as part of these
reports, no comprehensive analysis of the cases, presenta-
tion, or management exists.MATERIALS AND METHODS
The objective was to review comprehensively the literature
on the reports, presentation, diagnosis, and management of
AS in AVF to date.Data sources and search strategy
In April 2015 a predetermined search query (“angiosarcoma
AND arteriovenous ﬁstula”) was used to search the Embase,
AMED, Health Management Information Consortium
(HMIC), and MEDLINE databases utilising the OVIDSP
(EMBASE, AMED, and HMIC), and the PubMed (MEDLINE)
interfaces. All databases were searched from inception.
Additional articles were retrieved using hyperlinks, via ref-
erences, other sources, or an internet search.Study selection
Articles were selected for review according to the following
criteria: original article or case describing or discussing AS
with respect to dialysis-related AVF or grafts. Articles in
other languages were retrieved and data were extracted
with the aid of a native speaker. Exclusion criteria included
articles not describing an AS case, not related to AVF, and
articles that were only reviews or comments. Two reviewers
(Y.O. and K.R.) independently assessed all retrieved articles
and disagreements were resolved by consensus.Data extraction
Data were extracted by two authors (Y.O. and K.R.) inde-
pendently, using a predetermined data extraction tool.
Extracted points mirrored those in Table 1.
Data were entered and tabulated in Word 2013 (Micro-
soft, Redmond, WA, USA) and descriptive statistical analysis
performed using Excel 2013 (Microsoft). The study was
planned, conducted, and reported in adherence to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) standards.RESULTS
The search strategy returned 101 results, of which 18 were
accepted and a further two added via other sources (Fig. 1).
Overall, 20 were accepted for inclusion into the ﬁnal review
(Table 1).Article types and levels of evidence
The majority of articles were published case reports (17/20;
85.0%) and one (5.0%) was a published case report with
review. Two were not published; one was a seminar case
report and one was a case presentation. All articles were
assessed as being evidence level V.Patient demographics
Two case reports concerned an identical patient; thus, 22
unique patients were identiﬁed overall. Of these the ma-
jority (n ¼ 20; 90.9%) were men; mean  SD age was
54.9  13.6 years. AVF were most often reported in the
right arm (n ¼ 11; 50.0%) and in one case the laterality was
unspeciﬁed. AVF types were most often brachiocephalic
(n ¼ 14; 63.6%) with other sites being radiocephalic (n ¼ 4;
18.2%) or unspeciﬁed (n ¼ 3; 13.6%). One (4.5%) case was
in association with a polytetraﬂuoroethylene (PTFE) graft.
Nineteen cases (86.4%) were post-transplant and 18
(81.8%) were immunosuppressed, the discrepancy being
due to one case where the transplant was removed and the
patient subsequently continued on haemodialysis without
immunosuppression. With regard to immunosuppressive
regimen, four (18.2%) cases reported triple therapy, seven
(31.8%) reported double therapy, and two (9.1%) reported
monotherapy. The agents used were corticosteroids
(n ¼ 10; 45.5%), ciclosporin (n ¼ 6; 27.3%), azathioprine
(n ¼ 7; 31.8%), tacrolimus (n ¼ 4; 18.2%), and mycophe-
nolate (n ¼ 1; 4.5%). Two (9.1%) reports did not state what
agent was used, and three (13.6%) did not state if patients
were receiving immunosuppressive treatment. Transplants
from deceased donors were the most commonly reported
(n ¼ 11; 50.0%) followed by live transplants (n ¼ 4; 18.2%).
Four (18.2%) reports did not report a transplant type and
three (13.6%) cases did not have transplantsDisease presentation
Pain at a previously asymptomatic AVF site was the most
common initial presenting complaint (n ¼ 17; 77.3%), either
alone or in combination with mass/swelling (n ¼ 12; 54.5%)
and/or bruising and bleeding (n ¼ 3; 13.6%). Three (13.6%)
cases presented with only mass, one (4.5%) case with only
bleeding, and one (4.5%) case was reported in an arterio-
venous PTFE graft and presented with recurrent infections.
Initial presenting pattern was most often with two symp-
toms (n ¼ 11; 50.0%); only two (9.1%) presented with three
symptoms.
The mean  SD time to presentation, in those cases that
reported it, from AVF formation was 118.9  57.5 months,
while the time from transplant was 96.9  70.0 months. All
reported cases were of epithelioid AS.Diagnostic interval
Seven (31.8%) cases did not report an initial/working
diagnosis. Of those that did, thrombosis (n ¼ 7; 31.8%)
either alone (n ¼ 4; 57.1%) or with infection (n ¼ 3; 42.9%)
was the most often initial diagnosis made of the presenting
Table 1. Summary of data extracted from case reports.
Reference Sex Age
(y)
Presenting
symptom
Site AVF status Transplant
status
Immuno-
suppression
status
Initial
diagnosis
Delay to
diagnosis
Investigations
(chronological
order)
Histology Time
from
AVF to
AS
(approx.
mo)
Time
from
transplant
to AS
(approx.
mo)
Management Mean
survival
(mo)
Arun et al.
(2011)25
M 52 Pain and mass RBC Excised Functioning
(DD)
NS NS NS Excision histology Epithelioid NS 144 NS NS
Baroudjian
et al. (2013)26
M 69 Bleeding LBC Ligated at time
of transplant
Functioning
(NS)
NS Thrombosed
false aneurysm
2 wk Skin deposit
biopsy
Epithelioid 144 120 Chemotherapy Deceased
(survival
not stated
but short)
Bessis et al.
(1998)4
M 61 Pain RBC Functioning,
unused
Functioning
(DD)
Ciclosporin,
corticosteroid,
azathioprine
Thrombosis 6 wk Skin deposit
biopsy, X-ray, CT
Epithelioid 84 60 Amputation 11.0
Byers et al.
(1992)23
Parrott et al.
(1993)24
M 28 Pain &
swelling
RRC Functioning,
unused
Functioning
(DD)
Ciclosporin,
corticosteroid
Infection and
thrombosis
22 wk Lesion biopsy, X-
ray, CT, MRI
NS 144 96 Amputation 16.0
Chanyaputhipong
et al. (2011)27
M 57 Pain and mass LRC Thrombosed
and
aneurysmal
Dialysing via
right RC
Removed (DD) No Infection and
granuloma
NS Excision histology,
MRI
Epithelioid 204 NA Excision and
radio-/
chemotherapy
11.0
M 63 Pain and mass LBC Thrombosed
and
aneurysmal
Dialysing via
RBC
Never No AVM ?AS NS MRI, excision
histology
Epithelioid 108 NA Excision and
radio-/
chemotherapy
9.5
Conlon et al.
(1993)9
M 40 Mass RBC Ligated
(aneurysmal)
First removed
(DD), second
functioning
(DD)
Corticosteroid and
Azathioprine
NS NS Excision histology,
angiogram, X-ray,
CT, isotope bone
scan
Epithelioid 204 84 Skeletonisation
resection,
radio-/
chemotherapy
5.0
Demey et al.
(2014)5
M 80 Pain and mass LBC Disused:
stenosis and
low ﬂow
Dialysing via
Hickman line
Never No Aneurysm 40 wk X-ray, CT, excision
histology
Epithelioid 54 NS None 10.0
Farag et al.
(2005)28
M 39 Mass RAVF Aneurysmal
ligated
First removed
(SPK), second
functioning
(DD)
Ciclosporin,
azathioprine,
corticosteroids
Thrombosis NS Excision histology,
CT
Epithelioid 156 144 Excision and
chemotherapy
11
Fisher (2009)29 M 56 Pain, swelling,
bruising
AVF NS Functioning
(NS)
NS NS NS Lesion biopsy Epithelioid NS NS Amputation NS
Jansen and
McHargue
(2013)30
M 58 Pain LAVF NS Functioning
(DD)
Yes (NS) Dermatological NS Skin deposit
biopsy
Epithelioid NS NS NS NS
Continued
Table 1-continued
Reference Sex Age
(y)
Presenting
symptom
Site AVF status Transplant
status
Immuno-
suppression
status
Initial
diagnosis
Delay to
diagnosis
Investigations
(chronological
order)
Histology Time
from
AVF to
AS
(approx.
mo)
Time
from
transplant
to AS
(approx.
mo)
Management Mean
survival
(mo)
Keane and Carney
(1993)31
M 41 Mass RBC Aneurysmal
ligated
First rejected
(DD), second
functioning
(DD)
Corticosteroids
and azathioprine
NS NS Excision histology,
CT, X-ray
NSdappears
epithelioid
from
histology
216 84 Excision, radio-/
chemotherapy
8.0
Kim et al. (2012)32 M 70 Recurrent
infections
RAVG NS Functioning
(DD)
Yes (NS) Infection NS but
long
MRI, excision
histology
Epithelioid 120 84 Resection and
chemotherapy
NS
Makhdoomi et al.
(2015)33
F 79 Pain and
swelling
LBC Failed without
use
Dialysing via
PD
Never No Infection and
thrombosis
NS Duplex USS,
excision histology
NSdappears
epithelioid
as CD31þ
132 NS Excision and
radiotherapy
NS
Medioni et al.
(1996)34
M 60 Pain and mass RBC Functioning Functioning
(NS)
Ciclosporin and
corticosteroids
NS NS Excision histology Epithelioid 84 60 Amputation 11.0
Murata et al.
(2011)35
M 40 Pain and
bleeding
LRC Excised,
aneurysmal
and
thrombosed
Functioning
(live related)
Corticosteroids
and azathioprine
NS NS Skin deposit
biopsy, MRI
NSdappears
epithelioid
from
histology
NS 300 Amputation Survived
Patapas et al.
(2013)6
M 58 Pain and
swelling
LBC Functioning Functioning
(NS)
Corticosteroid,
ciclosporin,
azathioprine
Abscess 3 mo (Dx
after
death)
Excision histology,
CT
Epithelioid 108 96 Resection 3.0
Qureshi et al.
(2010)36
M 48 Pain, swelling,
discolouration
RBC Ligated Functioning
(live)
Corticosteroid and
tacrolimus
NA NA Excision histology,
CT
Epithelioid 36 24 Amputation Survived
Webster et al.
(2011)37
M 59 Pain and
swelling
RBC Excised Functioning
(live
unrelated)
Tacrolimus Infection and
thrombosis
NS Excision histology Epithelioid 36 24 Amputation Survived
F 41 Pain RBC Thrombosed Functioning
(live related)
Tacrolimus NS 4 weeks MRI, skin deposit
biopsy
Epithelioid 72 36 NS 4.0
M 44 Pain and mass LBC NS Functioning
(DD)
Tacrolimus and
mycophenolate
NS 13 weeks Lesion biopsy Epithelioid 156 96 NS 6.0
Wehrli et al.
(1998)38
M 64 Pain LRC Occluded Functioning
(DD)
Corticosteroid,
ciclosporin,
azathioprine
Thrombosis Mo (not
stated)
Skin deposit
biopsy, MRI, CT
Epithelioid 120 84 Amputation
and
radiotherapy
Multiple
metastases
at 6 mo
Note. AVF ¼ arteriovenous ﬁstula (unclassiﬁed); AS ¼ angiosarcoma; M ¼ male; F ¼ female; RBC ¼ right brachiocephalic; DD ¼ deceased donor; NS ¼ not stated; LBC ¼ left brachiocephalic;
CT ¼ computed tomography; RRC ¼ right radiocephalic; MRI ¼ magnetic resonance imaging; LRC ¼ left radiocephalic; RC ¼ radiocephalic; NA ¼ not available; RAVF ¼ right AVF;
SPK ¼ simultaneous pancreas kidney; LAVF ¼ left AVF; RAVG ¼ right arteriovenous graft; PD ¼ peritoneal dialysis; USS ¼ ultrasound scan; Dx ¼ diagnosis.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses ﬂow diagram.
Angiosarcoma and Dialysis-related Arteriovenous Fistulae 131symptoms. Two cases (9.1%) were suspected to be due to
infection alone and one (4.5%) due to infection with un-
derlying granuloma. One case was a referral to dermatology
due to overlying skin changes and another was thought to
be aneurysmal change. In only one case was a diagnosis of
AS entertained, but the ﬁrst diagnosis was an arteriovenous
malformation. Owing to the previously established diag-
nosis, one case was a referral to a sarcoma centre.
Eight (36.4%) cases reported the time taken between
initial presentation and AS diagnosis; this diagnostic interval
ranged between 2 and 40 weeks. In two cases three surgical
procedures were done on the AVFs without histology
specimens being sent.4,5 Diagnosis was eventually made
once cutaneous manifestations of AS were seen and a skin
biopsy sent for histology revealed the primary diagnosis. In
one case diagnosis was only made at autopsy.6Investigations
In all cases the diagnosis was made via histology; biopsy of
skin deposits (n ¼ 6; 27.3%), biopsy of the lesion directly
(n ¼ 3; 13.6%), or histology of surgically resected/excised
sample (n ¼ 13; 59.1%). In seven (31.8%) cases magnetic
resonance imaging (MRI) was used to assess local tumour
characteristics. Angiography and duplex ultrasound were
used as the initial imaging modality in one (4.5%) case each.
Computed tomography (CT) imaging (n ¼ 9; 40.9%), plain
radiographs (n ¼ 5; 22.7%), CTepositron emissiontomography (PET) (n ¼ 1; 4.5%), and bone isotope scanning
(n ¼ 1; 4.5%) were used for staging purposes or local
characterisation. Six (27.3%) cases reported histology as the
only investigation modality.Disease outcome and management
Survival time from diagnosis was reported in 12 (54.5%)
cases, with a mean  SD survival time of 8.8  3.7 months;
all mortality cases had signiﬁcant metastatic disease. Three
(13.6%) patients were stated as surviving with no disease,
one patient was alive with pulmonary metastasis, one pa-
tient died shortly after the ﬁrst round of chemotherapy with
no survival time given, and one patient died with a diag-
nosis made only after autopsy.
Amputation and resection/excision were the most often
reported deﬁnitive management (both n ¼ 8 each; 36.4%),
both either alone or in combination with radio- or
chemotherapy. One patient was managed with chemo-
therapy alone. Four cases (18.2%) did not report a man-
agement type and in one case no treatment was given (in
accordance with patient wishes). Overall amputation
appeared to offer better survival but the data are incom-
plete and very limited.
DISCUSSION
AS are rare but highly aggressive tumours with potent
metastatic potential arising from endothelial tissue. Only
132 Y. Oskrochi et al.2% of sarcomas are AS and although the majority are
thought to arise spontaneously, risk factors do exist.7
Chronic lymphoedema of all types, including postsurgical,
has been demonstrated as being associated with AS. With
respect to AVF, altered lymphoid dynamics surrounding
these sites mimics lymphoedema and thus may contribute
to AS development, with previous reports suggesting that
the altered regional lymphatic ﬂow could also cause a
localised immunosuppressive environment,8,9 further con-
founding this effect. Implantable material has also been
suggested as a causative factor with PTFE/dacron, plastic,
and other synthetic grafts in vascular settings,10e15 as well
as surgical gauze/sponge, and metal plates in nonvascular
settings being implicated.16e19
Immunosuppression is a known risk factor for increased
rates of all malignancies; reported standardised incidence
ratios (SIR) amongst the immunosuppressed population are
double that of the normal population (SIR 2.10; 95% con-
ﬁdence interval 2.06e2.14),20,21 and therefore, at least in
immunocompromised patients, this is likely to play a sig-
niﬁcant role. Nevertheless, compared with other immune
compromised malignancies, such as EpsteineBarr virus-
associated post-transplant lymphoproliferative disease or
human herpesvirus-8-associated Kaposi sarcoma however,
no pathogen has been linked to AS development.22 With
respect to the present review the role of immunosup-
pression remains equivocal; although most were immuno-
compromised, one case reported that immunosuppressive
therapy was decreased after diagnosis with no reported
effect on the disease course, and in four cases the patients
were not immunocompromised at the time of diagnosis;
three never having immunosuppressive treatment and one
having had treatment stopped some time prior to
diagnosis.
Diagnostic assessment of suspected AS should always
include biopsy. Histologically, AS appear as abnormal pleo-
morphic malignant endothelial cells, which, architecturally,
may be multilayered or form papillary projections into the
vascular lumen. Cells also classically express CD34, CD31,
vascular endothelial growth factor, or von-Willebrand Fac-
tor, and, as with other malignancies, the degree of struc-
tural abnormality is directly related to the grade and
therefore aggressiveness of the tumour.7
Work-up for AS should include local and systemic imag-
ing. For local imaging, MRI is the modality of choice to
assess soft tissue and macroscopic tumour characteristics
such as size and local invasion. CT or PET imaging may then
be used for systemic imaging to stage the disease in
accordance with the TNM classiﬁcation for soft tissue sar-
comas.23 Treatment of choice should be coordinated with
local specialist sarcoma centres; however, from the limited
evidence available amputation appears to offer the best
prognosis compared with resection or excision. Local
recurrence risk with resection is high and adjuvant che-
moradiotherapy does not appear to offer an improved
prognosis. In cases of metastatic disease, there is no
consensus on chemotherapy regimen or even overall
beneﬁt.7Strengths and limitations
The ﬁrst comprehensive review of AS in haemodialysis
associated AVFs, including two previously unpublished
cases, has been presented.6,24 The strengths of this review
are in the number of cases retrieved and the diversity of
data extracted. However, the limitations are also in the
limited number of case reports available and therefore the
restricted conclusions that can be drawn. Nevertheless, this
is a useful platform for future research to use as a reference
tool for this uncommon but important pathology.
CONCLUSION
AS is a rare complication of AVF. It should be considered a
differential diagnosis in patients who present with new
onset intractable pain, bruising, or enlarging mass around a
previously quiescent AVF site, regardless of the ﬁstula’s
functional status. Unusual presentations of these symptoms
or an atypical clinical course should raise further concern
that there may be underlying AS.
Suspected AS should be investigated by MRI for local
characterisation, and a biopsy should always be taken for
histological conﬁrmation. Staging should be performed by
CT and deﬁnitive management should be guided by local
specialist sarcoma centres. This review suggests that
amputation may offer the best survival, but the evidence is
weak.
The practice in the authors’ institution is to send all
specimens from AVF excisions for histology as a matter of
course. Despite the likely low yield, it is believed that a
positive result would potentially save lives, owing to early
identiﬁcation.
Ultimately, AS is a rare complication of AVF; however,
owing to the poor prognosis and aggressive nature, early
identiﬁcation and deﬁnitive management within a multi-
disciplinary approach can be life saving.
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